Raymond James reissued their outperform rating on shares of Immunovant (NASDAQ:IMVT – Free Report) in a research note issued to investors on Thursday, MarketBeat reports. Raymond James currently has a $36.00 target price on the stock. Several other research firms also recently weighed in on IMVT. JPMorgan Chase & Co. decreased their price objective on […]

Raymond James reaffirmed their market perform rating on shares of Biogen (NASDAQ:BIIB – Free Report) in a research note released on Thursday morning, Marketbeat reports. Several other research analysts have also recently weighed in on the company. Robert W. Baird lowered their target price on Biogen from $316.00 to $294.00 and set an outperform rating […]

Raymond James reaffirmed their outperform rating on shares of Immunovant (NASDAQ:IMVT – Free Report) in a research note published on Thursday, Marketbeat.com reports. The firm currently has a $36.00 price target on the stock. IMVT has been the subject of several other reports. UBS Group lowered their price target on Immunovant from $42.00 to $41.00 […]

Raymond James reaffirmed their market perform rating on shares of ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) in a research report report published on Thursday morning, Marketbeat.com reports. A number of other research analysts have also recently issued reports on the company. StockNews.com raised ACADIA Pharmaceuticals from a buy rating to a strong-buy rating in a […]